Participated in Celea Therapeutics' $180M financing to advance deupirfenidone as a potential new standard of care for idiopathic pulmonary fibrosis.
Celea Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering transformative treatments for people with serious respiratory diseases
Celea Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering transformative treatments for people with serious respiratory diseases. Its lead program, deupirfenidone, is in Phase 3 development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.